Zoetis Announces USDA Vaccine Licensures to Help Veterinarians Address Canine Infectious Respiratory Disease (CIRD)
• New Vanguard® Rapid Resp Intranasal and Vanguard® B Oral vaccines offer veterinarians the flexibility of multiple formulations and mucosal delivery options
• Veterinarians can help provide canine patients with additional protection by boosting with Bronchicine® CAe and Vanguard® Plus 5 systemic vaccines
• Zoetis has also recently received USDA licenses for Vanguard® crLyme and the first conditional license for Canine Influenza Vaccine, H3N2, Killed Virus*
FLORHAM PARK, N.J. – February 29, 2016 – Zoetis Inc. today announced that it has received licenses from the U.S. Department of Agriculture (USDA) for new Vanguard® Rapid Resp Intranasal and Vanguard® B Oral vaccines, which may be ordered through Zoetis or key distributors including Henry Schein, Midwest, MWI, and Patterson. Zoetis is the first and only manufacturer to offer oral, intranasal and injectable options for vaccinating dogs against Bordetella bronchiseptica (Bb), which is considered a common pathogen in canine infectious respiratory disease (CIRD).
“The protocol for preventing CIRD varies greatly depending on the lifestyle and temperament of the dog, so we’re pleased to offer the broadest range of vaccine options available,” said Shelley Stanford, DVM, Group Director, Companion Animal Division Veterinary Professional Services, Zoetis. “A selection of antigen combinations and modes of administration makes it easy and convenient for veterinarians to choose the vaccination protocol that best suits the needs of their patients.”
About VANGUARD® Rapid Resp and VANGUARD® B Oral Vaccines
The Vanguard® Rapid Resp Intranasal line of vaccines is for administration to healthy dogs eight weeks of age or older as an aid in preventing respiratory disease caused by canine adenovirus Type 2 (CAV-2), canine parainfluenza caused by canine parainfluenza virus (CPiV), and respiratory disease caused by Bb. Available in three-way (Bb, CPiV, CAV-2), two-way (Bb, CPiV) and one-way (Bb) options, it has the first approved 1-year duration of immunity for Bordetella bronchiseptica. Annual revaccination with a single dose is recommended. It works fast and is safe and effective.1, 2
Vanguard® Rapid Resp presents the broadest line of 0.5 mL intranasal respiratory vaccines available with both syringe and syringe-free administration options for all antigenic offerings.
In a clinical study, Vanguard® Rapid Resp vaccines were shown to reduce the duration of coughing in dogs by 84.4% following Bb challenge, and also to reduce other clinical signs, such as nasal discharge and retching.1
A field safety study in 614 client-owned dogs showed that Vanguard® Rapid Resp is safe and well-tolerated, with no abnormal health events or reactions reported in the immediate post-vaccination period. The most common adverse events during the late phase post-vaccination period, reported in fewer than 2% of animals, were sneezing (1.30%); cough (1.14%); emesis (0.49%); lethargy (0.49%); pyrexia (0.33%); rhinitis (0.33%); anorexia (0.16%) and pruritus (0.16%).1
Vanguard® B Oral vaccine aids in preventing canine infectious tracheobronchitis (kennel cough) caused by Bb in healthy dogs eight weeks of age or older. It is safe, effective and convenient. It is the first canine oral Bb vaccine available with both syringe and syringe-free options. Annual revaccination is recommended.
The efficacy and safety of Vanguard® B Oral is supported by laboratory and field safety studies. In a field safety study with 321 client owned dogs, no serious adverse events were noted. Mild side effects including diarrhea, vomiting and lethargy were observed in 16 dogs and quickly resolved with supportive care.
In both dogs and humans, it has been demonstrated that there may be a beneficial effect when vaccines are administered via different routes. In dogs it has been demonstrated that when intranasal Bordetella bronchiseptica vaccines are used for initial vaccination and injectable vaccines are used for subsequent doses, immune responses may be improved.3, 4 Similar techniques combining oral and injectable vaccines have been demonstrated to provide a more robust immune response in humans.5 Zoetis is excited to be the only company to offer veterinarians the capability to use this concept for vaccination of their canine patients against B.bronchiseptica.
Canine infectious respiratory disease (CIRD) is a complex syndrome caused by a variety of highly contagious viruses and bacteria, including CAV-2, CPiV and Bb, among others. Often called "Kennel Cough", it is one of the most prevalent respiratory conditions in dogs.6 Clinical signs of CIRD include: dry cough; hacking; retching; honking sound when coughing; watery discharge from nose or eyes; lethargy; fever; and loss of appetite. Left untreated, CIRD can lead to pneumonia and, in extreme cases, death. Typically, CIRD is treated with supportive care and antibiotics when appropriate.6
According to the American Veterinary Medical Association (AVMA), dogs that are frequently in social situations with other dogs – such as in boarding facilities or day care – can be at especially high risk of infection with CIRD.7
Zoetis offers a broad range of flexible solutions, including Bronchicine® CAe (injectable); Vanguard® Plus 5; Vanguard® CIV (H3N8); the new Canine Influenza Vaccine, H3N2, Killed Virus; and now, Vanguard® Rapid Resp Intranasal and Vanguard® B Oral vaccines.
For more information about Zoetis vaccines, visit [www.zoetis.com] or call Zoetis Customer Service at 888-ZOETIS-1.
Zoetis (Zoetis (zô-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health,
Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2015, the company generated annual revenue of $4.8 billion with approximately 9,000 employees. For more information, visit www.zoetis.com.
For Further Information, Contact:
1.Data on file, Study Report No. 3161-R-60-11-498, Zoetis Inc.
2.Data on file, Study Report No. B961-R-US-14-147, Zoetis Inc .
3.Ellis J, Haines D, West K, et al. Effect of vaccination on experimental infection with Bordetella bronchiseptica in dogs. JAVMA. 2001;218(3):367-375.
4.Ellis J, Krakowka GS, Dayton A., et al. Comparative efficacy of an injectable vaccine and an intranasal vaccine in stimulating Bordetella bronchiseptica-reactive antibody responses in seropositive dogs. JAVMA. 2002;220(1):43-48.
5.John J, Giri S, Karthikeyan A, et al. Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: an open-label, randomized control trial. Lancet. 2014;384:1505-12.
6.https://www.vetinfo.com/canine-infectious-respiratory-disease.html. Accessed 11/22/15.
7.https://www.avma.org/KB/Resources/Reference/Pages/Canine-Influenza-Backgrounder.aspx. Accessed 2/22/16.
All trademarks are the property of Zoetis Inc., its affiliates and/or its licensors. Zoetis Inc. All rights reserved. February 2016. SAB-00265
*This product license is conditional. Efficacy and potency studies are in progress.
- Belgium (French)
- Belgium (Dutch)
- Costa Rica
- Czech Republic
- New Zealand
- South Africa
- South Korea
- United Kingdom
- United States